SINGLE-AGENT LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PATIENTS

被引：0
|
作者：
Puccini, B. [1 ]
Chitarrelli, I. [1 ]
Antognoli, G. [1 ]
Fabbri, A. [1 ]
Rigacci, L. [1 ]
Lenoci, M. P. [1 ]
Lauria, F. [1 ]
Bosi, A. [1 ]
机构：
[1] Dept Hematol, Florence, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0687
引用
收藏
页码：288 / 288
页数：1
相关论文
共 50 条
  • [41] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
  • [42] SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES
    Witzig, T.
    Vose, J.
    Zinzani, P.
    Habermann, T.
    Tuscano, J.
    Sinha, R.
    Williams, M.
    Drach, J.
    Ramchandren, R.
    Besisik, S.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Goy, A.
    HAEMATOLOGICA, 2013, 98 : 130 - 131
  • [43] Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
    Pettengell, Ruth
    Coiffier, Bertrand
    Narayanan, Geetha
    Hurtado de Mendoza, Fernando
    Digumarti, Raghunadharao
    Gomez, Henry
    Zinzani, Pier Luigi
    Schiller, Gary
    Rizzieri, David
    Boland, Giles
    Cernohous, Paul
    Wang, Lixia
    Kuepfer, Christine
    Gorbatchevsky, Igor
    Singer, Jack W.
    LANCET ONCOLOGY, 2012, 13 (07): : 696 - 706
  • [44] Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Trappe, Ralf
    Riess, Hanno
    Babel, Nina
    Hummel, Manfred
    Lehmkuhl, Hans
    Jonas, Sven
    Anagnostopoulos, Ioannis
    Papp-Vary, Matthias
    Reinke, Petra
    Hetzer, Roland
    Doerken, Bernd
    Oertel, Stephan
    TRANSPLANTATION, 2007, 83 (07) : 912 - 918
  • [45] Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide
    S Park
    D Vassilieff
    V Bardet
    F Viguié
    F Dreyfus
    Leukemia, 2010, 24 : 1960 - 1962
  • [46] Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
    Chen, Christine I.
    Bergsagel, P. Leif
    Paul, Harminder
    Xu, Wei
    Lau, Anthea
    Dave, Nimisha
    Kukreti, Vishal
    Wei, Ellen
    Leung-Hagesteijn, Chungyee
    Li, Zhi Hua
    Brandwein, Joseph
    Pantoja, Mariela
    Johnston, James
    Gibson, Spencer
    Hernandez, Tiffany
    Spaner, David
    Trudel, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1175 - 1181
  • [47] Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide
    Park, S.
    Vassilieff, D.
    Bardet, V.
    Viguie, F.
    Dreyfus, F.
    LEUKEMIA, 2010, 24 (11) : 1960 - 1962
  • [48] INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Richards, Tiffany
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E144 - E145
  • [49] Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
    Grommes, Christian
    Pastore, Alessandro
    Gavrilovic, Igor
    Kaley, Thomas
    Nolan, Craig
    Omuro, Antonio M.
    Wolfe, Julia
    Pentsova, Elena
    Hatzoglou, Vaois
    Mellinghoff, Ingo
    DeAngelis, Lisa
    BLOOD, 2016, 128 (22)
  • [50] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
12345